<DOC>
	<DOCNO>NCT02946385</DOCNO>
	<brief_summary>The purpose study compare effectiveness 2 ( give 0 , 2 month ) 3 ( give 0 , 2 , 6 month ) dose GSK MenABCWY vaccine administer healthy adolescent study V102_15 ( NCT02212457 ) , panel randomly select U.S. N. meningitidis serogroup B invasive disease strain 24 month last meningococcal vaccination V102_15 ( NCT02212457 ) response booster dose .</brief_summary>
	<brief_title>Study Assess Immunological Long-term Persistence Antibodies ( Abs ) 2 Years After GlaxoSmithKline ( GSK ) Meningococcal ABCWY Vaccination V102_15 ( NCT02212457 ) Response Booster Adolescents</brief_title>
	<detailed_description>Naive subject randomize 1:1 receive MenABCWY rMenB+OMV Day 1 . No randomization treatment arm follow-on subject require vaccine group remain parent study V102_15 ( NCT02212457 ) . Response booster dose MenABCWY vaccine also assess follow-on subject receive 2 3 dos MenABCWY ( 0.2- , 0 , .6- 0 , .2 , .6-month schedule ) parent study , compare response single dose MenABCWY naive subject ( subject meningococcal vaccine-naive similar age subject enrol parent study ) . Response booster dose GSK Meningococcal B Recombinant vaccine ( rMenB+OMV ) assess subject receive 2 dos rMenB+OMV ( 0 , 2-month schedule ) parent study , compare response single dose rMenB+OMV naive subject .</detailed_description>
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<criteria>Followon Participants Subjects Finland Poland previously enrol study V102_15 ( NCT02212457 ) receive planned meningococcal vaccination study Who receive additional meningococcal vaccination since last meningococcal vaccination administer parent trial . Who give write informed consent assent nature study explain accord local regulatory requirement , prior study entry . If subject age 18 time enrollment , parent ( ) / legal guardian ( ) subject give write consent . Individuals investigator believe comply requirement protocol . Individuals good health determine outcome medical history , physical examination clinical judgment investigator . Naive Group Male female individual similar age ( approximately 1220 year ) followon subject V102_15 ( NCT02212457 ) trial . Who receive meningococcal vaccination since birth Individuals give write informed consent assent nature study explain accord local regulatory requirement , prior study entry . If subject age 18 time enrollment , parent ( ) / legal guardian ( ) subject give write consent . Individuals investigator believe comply requirement protocol . Individuals good health determine outcome medical history , physical examination clinical judgment investigator . Followon Participants : Followon individual eligible enrol study : History meningococcal vaccine administration since last meningococcal vaccination administer V102_15 ( NCT02212457 ) parent study . Current previous , confirm suspected disease cause N. meningitidis , since termination parent study . Household contact and/or intimate exposure individual laboratory confirm N. meningitidis infection within 60 day enrollment . If subject female childbearing potential , sexually active , use acceptable contraceptive method least 2 month prior study entry duration trial . Pregnancy breastfeed History severe allergic reaction previous vaccination hypersensitivity vaccine component include diphtheria toxoid ( CRM197 ) latex . Progressive , unstable uncontrolled clinical condition . Any confirm suspected condition impaired/altered function immune system . Chronic administration immunosuppressant immunemodifying drug within three month prior study vaccination plan use throughout study period . ( For corticosteroid , mean prednisone , equivalent , ≥ 20 mg/day . Inhaled , intranasal topical steroid allow ) . Administration blood , blood product and/or plasma derivative parenteral immunoglobulin preparation 3 month prior study enrolment . Received investigational nonregistered medicinal product within 30 day prior informed consent . Administration vaccine within 14 day 28 day prior enrollment study , within 7 day vaccination study . Clinical condition represent contraindication intramuscular vaccination and/or blood draw . Who receive systemic antibiotic treatment within 3 day prior blood draw Any clinical condition , opinion investigator , might pose additional risk subject due participation study . Naive Individuals Naive individual eligible enrol study : History meningococcal vaccine administration since birth . Current previous , confirm suspected disease cause N. meningitidis . Household contact and/or intimate exposure individual laboratory confirm N. meningitidis infection within 60 day enrollment . If subject female childbearing potential , sexually active , use acceptable contraceptive method least 2 month prior study entry duration trial . Pregnancy breastfeed . History severe allergic reaction previous vaccination hypersensitivity vaccine component include diphtheria toxoid ( CRM197 ) latex . Progressive , unstable uncontrolled clinical condition . Any confirm suspected condition impaired/altered function immune system . Chronic administration immunosuppressant immunemodifying drug within 30 day prior study enrolment . ( For corticosteroid , mean prednisone , equivalent , ≥ 20 mg/kg/day . Inhaled , intranasal topical steroid allow ) . Administration blood , blood product and/or plasma derivative parenteral immunoglobulin preparation past 3 month plan use throughout study period . Received investigational nonregistered medicinal product within 30 day prior informed consent . Individuals part study personnel close family member conduct study . Administration vaccine within 14 day 28 day prior enrollment study , within 7 day first vaccination , and/or plan use vaccine 7 day prior 7 day second vaccination . Clinical condition represent contraindication intramuscular vaccination and/or blood draw . Who receive systemic antibiotic treatment within 3 day prior blood draw Any clinical condition , opinion investigator , might pose additional risk subject due participation study .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>meningococcal disease</keyword>
	<keyword>meningitis</keyword>
	<keyword>booster</keyword>
	<keyword>antibody persistence</keyword>
</DOC>